A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis

Phase 1

Recruiting

• Conditions: Ulcerative Colitis
• Interventions: Biological: BGP-014; Biological: Placebo

• Registration Number: NCT05118919
• Lead Sponsor: BioGaia Pharma AB

Brief Summary

The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of Lactobacillus reuteri BGP-014 in mild to moderate active Ulcerative Colitis (UC) patients as an oral administered local treatment in addition to Standard of Care (SoC) treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-10-26
• Study First Submitted QC: 2021-11-02
• Study First Posted: 2021-11-12
• Study Start: 2022-02-09
• Status Verified: 2023-02
• Last Update Submitted: 2023-02-13
• Last Update Posted: 2023-02-14
• Primary Completion: 2023-12
• Study Completion: 2023-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• The subject has given written consent to participate in the study.
• Diagnosed previously with UC (> 6 months earlier) determined by clinical and endoscopic histopathology (pathology showing chronic inflammatory changes). ≥1 documented previous flare-up and with last resolved flare >3 months away.
• Active UC determined by sigmoidoscopy before randomisation of study (baseline) and defined as a total Mayo index score of 4 to 10 points (endoscopic subscore ≥1, rectal bleeding ≥1).
• Permitted concomitant SoC medications include: Oral aminosalicylates (5-ASA), with a stable dose (1.6-4.8g/ day) for at least 12 days prior to screening, Visit 1. Steroids (dose ≤15mg at screening, Visit 1) with further tapering of dose in accordance with SoC until steroid tx termination. Immunomodulator, as: 6-Mercaptopurine, Azathioprine, Methotrexate (Stable dose for > 12 weeks prior to screening, Visit 1).
• Females of childbearing potential must use effective contraceptives

Exclusion Criteria

1. Involvement in any investigational drug or device study within 30 days prior to this study
2. Known intolerance of 5-ASA or sulphasalazine medications
3. Biologics or FMT treatment less than 12 weeks before screening
4. No 5-ASA or steroid topical treatment is allowed
5. Antibiotic treatment < 1 month prior the study
6. Unable to maintain stable dose of NSAIDs and PPIs
7. Evidence of on-going extensive colitis
8. Fever, defined as a temperature of >38.5 °C, at Visit 1
9. Anaemia, Hb value below 100
10. Evidence of on-going toxic megacolon
11. Presence of obstructive diseases of the gastrointestinal system
12. Any clinically significant concomitant disease that might interfere with patient safety
13. Unwilling to withdraw probiotic supplements. Yoghurts without supplemented bacteria are permitted
14. Pregnant
15. Planned abdominal surgery
16. Judged unable by the physician to comprehend information regarding the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Active	BGP-014	-
Placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
Frequency and severity of adverse events	Up to 10 weeks	The primary objective is to evaluate the safety and tolerability of BGP-014.

Trial Locations

Locations (4)

Gastroenterology Department, Ersta Hospital; 🇸🇪 Stockholm, Sweden

Gastroenterology Department, Danderyds Hospital; 🇸🇪 Stockholm, Sweden

Department of Medical Sciences Gastroenterology and Hepatology, Uppsala University Hospital; 🇸🇪 Uppsala, Sweden

Department of Gastroenterology and Hepatology, Linköping University Hospital; 🇸🇪 Linköping, Sweden